Kemp v. Regeneron Pharm., Inc.

117 F.4th 63
CourtCourt of Appeals for the Second Circuit
DecidedSeptember 9, 2024
Docket23-174
StatusPublished
Cited by11 cases

This text of 117 F.4th 63 (Kemp v. Regeneron Pharm., Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kemp v. Regeneron Pharm., Inc., 117 F.4th 63 (2d Cir. 2024).

Opinion

23-174-cv Kemp v. Regeneron Pharm., Inc.

United States Court of Appeals for the Second Circuit August Term, 2023

(Argued: January 25, 2024 Decided: September 9, 2024)

Docket No. 23-174-cv

_____________________________________

DENISE KEMP,

Plaintiff-Appellant,

v.

REGENERON PHARMACEUTICALS, INC.,

Defendant-Appellee. _____________________________________ Before:

LOHIER, LEE, and PÉREZ, Circuit Judges.

Plaintiff Denise Kemp, a manager at Renegeron Pharmaceuticals, Inc., spent the better part of June 2016 working remotely to take care of a child with a serious medical condition. Regeneron then prohibited her from working remotely for more than one day per week and required her to use intermittent leave under the Family and Medical Leave Act (FMLA) for any additional time away from the office. Kemp sued Regeneron, alleging interference with her rights under the FMLA, as well as discrimination, retaliation, and constructive discharge in violation of the New York State Human Rights Law (NYSHRL). Believing that the denial of FMLA benefits is an element of an unlawful interference claim, the United States District Court for the Southern District of New York (Román, J.) held that Kemp’s FMLA claim failed because Regeneron had not denied Kemp’s use of FMLA benefits. It determined that the claim was time-barred in any event. The District Court also held that Kemp’s NYSHRL claims failed on the merits. We hold that an employer can violate the FMLA merely by interfering with an employee’s use of FMLA benefits, even if the employer ultimately grants the benefits to which the employee is entitled. Because Kemp’s FMLA claim and NYSHRL claims for discrimination and retaliation were time-barred and her NYSHRL claim for constructive discharge fails on the merits, however, we AFFIRM.

STEPHEN BERGSTEIN, Bergstein & Ullrich, New Paltz, NY, for Appellant.

SHAWN MATTHEW CLARK, (Craig R. Benson, on the brief), Littler Mendelson, P.C., New York, NY, for Appellee.

Seema Nanda, Solicitor of Labor, Jennifer S. Brand, Associate Solicitor, Rachel Goldberg, Counsel for Appellate Litigation, Shelley E. Trautman, Attorney, U.S. Department of Labor, Washington, DC, for Amicus Curiae U.S. Department of Labor.

LOHIER, Circuit Judge:

The Family and Medical Leave Act (FMLA) entitles eligible employees to

take a total of 12 workweeks of leave from work during a one-year period to care

for a sick child, for example, 29 U.S.C. § 2612(a)(1), and makes it unlawful for an

employer “to interfere with, restrain, or deny the exercise of or the attempt to

exercise” an employee’s rights under the statute, id. § 2615(a)(1). The principal

question raised here is whether an employer who discourages but does not deny

an employee’s request for FMLA leave “interfere[s] with” the employee’s rights

2 in violation of the statute. The answer is yes. We nevertheless affirm the District

Court’s dismissal of Plaintiff Denise Kemp’s FMLA claim as time-barred because

her employer, Regeneron Pharmaceuticals, Inc., did not willfully violate the

statute so as to extend the two-year statute of limitations. We separately affirm

the dismissal of Kemp’s parallel state law claims under the New York State

Human Rights Law (NYSHRL).

BACKGROUND

Starting as an auditor in 2008, Kemp was employed by Regeneron for

nearly a decade until she retired on January 6, 2017. During her tenure, she was

promoted three times, in 2012, 2014, and 2016, with the latter two promotions

recommended by Teresa Rivenburgh, Kemp’s direct supervisor at all relevant

times. By 2016 Kemp had doubled her salary and risen to become a Senior

Manager in the Quality Assurance Department, supervising several employees.

Things changed in June 2016, when Kemp opted to work remotely in order

to care for a disabled daughter who was hospitalized with several serious

medical conditions. This was not the first time Kemp had been away from the

office for an extended period. She had previously taken leave for a number of

days in 2015 to care for her daughter, and from April 4 through May 15, 2016 she

3 took a short-term leave under the FMLA to have surgery. In both cases,

Regeneron approved the leave.

In June 2016 Kemp’s daughter underwent surgery, prompting Kemp to

work remotely from a hospital for 15 days while her daughter recovered. After

Kemp returned to the office, Rivenburgh and Rivenburgh’s supervisor, Patrice

Gilooly, voiced their concerns about the amount of time Kemp had been away.

“Rivenburgh told Kemp that [she] needed to be more visible in the office and

attend[] meetings in-person rather than by phone.” Joint App’x 444.

Rivenburgh, with Gilooly’s blessing, then limited Kemp to one day of remote

work per week, even though auditors in Kemp’s department regularly worked

from home and some non-managers worked remotely full-time. At about the

same time, however, Rivenburgh also encouraged Kemp to speak with someone

in Regeneron’s Human Resources Department about using paid time off or

intermittent FMLA leave rather than remote work for any additional days Kemp

spent away from the office.

On July 13, 2006, Kemp applied for intermittent FMLA leave to continue to

care for her daughter. Regeneron approved the leave, which was set to run from

August 9, 2016 through February 8, 2017. Around the same time, Kemp and

4 Rivenburgh began discussing Kemp’s possible transition to a role with a similar

status and title (senior manager) as her current position, but with fewer

managerial responsibilities. The parties dispute how these discussions began.

Kemp contends that Rivenburgh told her to consider a less demanding position,

while Gilooly and Rivenburgh testified that, to the contrary, Kemp “approached

[them] about wanting a change in her job.” Joint App’x 165.

Regeneron eventually developed a new senior manager position for Kemp

and, in October 2016, posted a job opening for the position that Kemp was set to

leave. At that point, Kemp did not consider the posting to be inappropriate

because she had agreed to move to the new position that had been developed for

her. Kemp formally accepted the new senior manager position in November

2016, with an expected start date in early 2017.

On December 19, 2016, however, less than a month after accepting the new

position, Kemp abruptly notified Regeneron that she planned to retire effective

January 6, 2017. According to Kemp, her decision to retire was spurred by

Regeneron’s refusal to let her work remotely, along with her belief that it was

“better to leave as a retirement, leave on good terms[,] than it [was] to quit”

because “[t]he pharmaceutical industry is a very small industry, and should [she]

5 apply for a position elsewhere [she] didn’t want to be blackballed.” Joint App’x

254–55. A Regeneron executive emailed Kemp to ask if there was anything he

could do to keep her at the company. On January 5, 2017, the day before Kemp

was scheduled to retire, the same executive offered to transfer her to a different

position. In keeping with her announcement the month before, however, Kemp

retired on January 6, 2017. A few months later, Kemp spoke with Regeneron

executives and employees about performing consulting work for the company;

the discussions went nowhere.

Kemp filed this action in New York state court on November 7, 2019,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
117 F.4th 63, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kemp-v-regeneron-pharm-inc-ca2-2024.